Aastrom Biosciences to Initiate U.S. Clinical Trial for Bone Formation in Spine Under Approved IND from the FDA
30 November 2005 - 10:00PM
PR Newswire (US)
-- Spine Fusion Trial at William Beaumont Hospital to Use Aastrom's
Adult Stem Cell TRC Product -- ANN ARBOR, Michigan, Nov. 30
/PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NASDAQ:ASTM)
today announced it will initiate a human clinical trial for the
evaluation of the Company's Tissue Repair Cell (TRC) product to
form new bone tissue in the spine. The Phase I/II trial will be
conducted under an Investigational New Drug (IND) application
approved by the U.S. Food and Drug Administration (FDA), and
initially conducted at a single clinical center, the William
Beaumont Hospital in Royal Oak, MI (Beaumont Hospital). Aastrom's
TRCs, a proprietary bone marrow-derived adult stem cell product,
will be used in posterior-lateral lumbar spinal fusions for
treatment of degenerative spondylolisthesis. This is the Company's
second FDA-approved, human clinical trial for local bone
regeneration using TRCs. This spine fusion clinical trial will be
conducted under the direction of Principal Investigator Harry
Herkowitz, M.D., Department Chair of Orthopedic Surgery at Beaumont
Hospital. Spine fusion is a procedure in which new bone tissue is
induced to fuse two or more vertebrae together to treat conditions
such as fractures of the vertebrae, or ruptured or lost disks.
Current therapy uses surgically transplanted bone tissue, as well
as other artificial bone materials and bone growth factors, to
induce the growth of new bone tissue. Aastrom proposes to use its
TRCs in combination with a carrier matrix to induce sufficient bone
growth to fuse or merge two vertebrae in the lower back, and
potentially eliminate the requirement for other more invasive or
less effective approaches. By stabilizing the spine, this procedure
reduces debilitating back pain, and helps a patient regain more
normal use of their legs. The primary purpose of this approved
clinical trial is to confirm that Aastrom's TRC product, when used
as a bone graft, is safe for use in posterior-lateral lumbar spinal
fusion surgery, and is able to generate new bone at the fusion
site, based on defined radiographic and clinical data. "With
clinical studies already using TRCs to generate jaw bone and to
repair severe bone fractures, we are very enthusiastic about this
new FDA- approved study to extend the evaluation of TRCs to a third
type of bone tissue," noted R. Douglas Armstrong, Ph.D., Chief
Executive Officer and Chairman of Aastrom. "We are also gratified
that this study is being conducted by an outstanding clinical team
led by Dr. Herkowitz at Beaumont Hospital." Aastrom's autologous
(patient-derived) TRC cell product is already being evaluated to
treat severe long bone fractures in an FDA-approved, multi-center
clinical trial in the United States, and the Company has reported
positive bone growth results from its fracture trial in Spain. TRCs
are also being evaluated for their ability to generate jaw bone in
a single center trial in Spain, to enable the placement of dental
implants. In addition, Aastrom recently announced that the first
clinical trial utilizing TRCs to treat limb ischemia in diabetic
patients was initiated at a center in Bad Oeynhausen, Germany.
About William Beaumont Hospital Department of Orthopedic Surgery
Beaumont's Department of Orthopedic Surgery offers leading edge
treatments and technology including minimally invasive surgery,
implants and trauma surgery. Beaumont is Michigan's most
experienced orthopedic hospital specializing in surgeries of the
back, neck, foot, ankle, hand and upper extremities, hip and knee
replacement, scoliosis treatment, tumor surgery, pediatric
orthopedics and sports medicine. Beaumont has been named among the
country's top hospitals for orthopedic care by U.S. News &
World Report and Solucient. Beaumont-Royal Oak is a 1,061-bed
tertiary care, teaching, research and referral center with Level I
trauma designation. It ranks first in the United States for
outpatient surgeries and second for inpatient surgeries. About
Tissue Repair Cells Tissue Repair Cells (TRCs) are Aastrom's
proprietary mixture of bone marrow-derived adult stem and
progenitor cells produced using patented single- pass perfusion
technology in the AastromReplicell(R) System. The clinical
procedure begins with the collection of a small sample of bone
marrow from the patient's hip in an outpatient setting. TRCs are
then produced in the automated AastromReplicell System over a
12-day period. It has been demonstrated in the laboratory that TRCs
are able to develop into different types of tissue lineages in
response to inductive signals, including blood, bone, cartilage,
adipose and vascular tubules. In previous clinical trials, TRCs
have been shown to be safe and reliable in regenerating certain
normal healthy bone marrow tissues. About Aastrom Biosciences, Inc.
Aastrom Biosciences, Inc. (NASDAQ:ASTM) is developing
patient-specific products for the repair or regeneration of human
tissues, utilizing the Company's proprietary adult stem cell
technology. Aastrom's strategic position in the tissue regeneration
sector is enabled by its proprietary Tissue Repair Cells (TRCs), a
mix of bone marrow-derived adult stem and progenitor cells
manufactured in the AastromReplicell(R) System, an industry- unique
automated cell production system. TRCs are the core component of
the products Aastrom is developing for severe bone fractures,
ischemic vascular disease, jaw reconstruction and spine fusion,
with Phase I/II level clinical trials active in the U.S. and EU for
some of these indications. For more information, visit Aastrom's
website at http://www.aastrom.com/. This document contains
forward-looking statements, including without limitation,
statements concerning planned clinical trials, product development
objectives, potential advantages of TRCs, and potential product
applications, which involve certain risks and uncertainties. The
forward-looking statements are also identified through use of the
words "potentially," and other words of similar meaning. Actual
results may differ significantly from the expectations contained in
the forward-looking statements. Among the factors that may result
in differences are potential patient accrual difficulties, clinical
trial results, potential product development difficulties, the
effects of competitive therapies, regulatory approval requirements,
the availability of financial and other resources and the
allocation of resources among different potential uses. These and
other significant factors are discussed in greater detail in
Aastrom's Annual Report on Form 10-K and other filings with the
Securities and Exchange Commission. CONTACTS: Kris M. Maly or Becky
Anderson Investor Relations Department Aastrom Biosciences, Inc.
Phone: (734) 930-5777 Cameron Associates Kevin McGrath --
Institutions Phone: (212) 245-4577 Alyson Nikulicz -- Media Phone:
(212) 554-5464 DATASOURCE: Aastrom Biosciences, Inc. CONTACT: Kris
M. Maly or Becky Anderson, Investor Relations Department of Aastrom
Biosciences, Inc., +1-734-930-5777; or Kevin McGrath -
Institutions, +1-212-245-4577 or Alyson Nikulicz - Media,
+1-212-554-5464, both of Cameron Associates Web site:
http://www.aastrom.com/
Copyright
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024